Patients could receive trastuzumab to complete therapy if T-DM1 was discontinued early. 2 Statistical methods and assumptions for the primary analysis have been described in detail 2; the same ...

Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD. Developed by Korean biosimilar specialists Samsung Bioepsis, MSD is the ...

Adjuvant therapy with trastuzumab emtansine has shown improved outcomes. New research findings are summarized in a short video.

The development, pharmacology, safety, efficacy, and dosage and administration of trastuzumab are reviewed. The discovery of HER2 gene amplification in up to 30% of women with breast cancer led to ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab ... which declined 31% to CHF 3.1 billion in the same period as biosimilars ate into its market share.

Targeted drugs hold great promise for the treatment of malignant tumors; however, there are several challenges for efficient evaluation of these drugs in preclinical and clinical studies.

There are three words that will stop you dead in your tracks and change your life forever. Likely, you or someone you know ...

On January 8, 2025, a bill prohibiting the sale of certain dietary supplements for weight loss and muscle building and other products to minors ...